Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Autoimmune Diseases
Interventions
DRUG

Efalizumab

1 mg/kg of efalizumab administered sub q once weekly

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER